<p>HbA1c monitoring, in-line with testing frequency guidelines, is needed to flag sub-optimally controlled patients who become ineligible for CCMDD enrollment. Patients receiving dual therapy may require special consideration. Addressing these shortfalls can assist in planning and implementation to achieve 2030 targets.</p>